Research programme: angiogenesis inhibitors - Alchemia

Drug Profile

Research programme: angiogenesis inhibitors - Alchemia

Alternative Names: ACL 16907; Somatostatin agonists - Alchemia; VT 16907

Latest Information Update: 29 Aug 2007

Price : $50

At a glance

  • Originator Alchemia
  • Class
  • Mechanism of Action Angiogenesis inhibitors; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Cancer; Diabetic retinopathy

Most Recent Events

  • 29 Aug 2007 Alchemia has discontinued development of ACL 16907 on commercial grounds
  • 04 Sep 2006 Discontinued - Preclinical for Age-related macular degeneration in Australia (unspecified route)
  • 07 Aug 2006 Preclinical trials in Age-related macular degeneration in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top